Back to Search
Start Over
ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy
- Source :
- Journal of Clinical Oncology. 34:TPS5087-TPS5087
- Publication Year :
- 2016
- Publisher :
- American Society of Clinical Oncology (ASCO), 2016.
-
Abstract
- TPS5087Background: At present, high-risk localized and locally advanced prostate cancer (PC) patients receiving primary radiation therapy (RT) and long-term androgen deprivation therapy (ADT; gonad...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
business.industry
medicine.medical_treatment
Apalutamide
030232 urology & nephrology
Locally advanced
Placebo
medicine.disease
Double blind
Androgen deprivation therapy
Radiation therapy
03 medical and health sciences
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
medicine
In patient
business
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........156e1e1e0987d20b833baa80659a0bad
- Full Text :
- https://doi.org/10.1200/jco.2016.34.15_suppl.tps5087